M
Mary V. Graham
Researcher at Washington University in St. Louis
Publications - 50
Citations - 6075
Mary V. Graham is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Lung cancer & Radiation therapy. The author has an hindex of 27, co-authored 50 publications receiving 5771 citations.
Papers
More filters
Journal ArticleDOI
Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.
Jay S. Cooper,Matthew D. Guo,Arnold Herskovic,John S. Macdonald,James A. Martenson,Muhyi Al-Sarraf,Roger W. Byhardt,Anthony H. Russell,Jonathan J. Beitler,Sharon A. Spencer,Sucha O. Asbell,Mary V. Graham,Lawrence L. Leichman +12 more
TL;DR: Combined therapy increases the survival of patients who have squamous cell or adenocarcinoma of the esophagus, T1-3 N0-1 M0, compared with RT alone, and severe acute toxic effects also were greater in the combined therapy groups.
Journal ArticleDOI
Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
Mary V. Graham,James A. Purdy,Bahman Emami,William B. Harms,Walter R. Bosch,Mary Ann Lockett,Carlos A. Perez +6 more
TL;DR: The V20 from the total lung DVH is a useful parameter easily obtained from most 3D treatment planning systems and may be useful in comparing competing treatment plans to evaluate the risk of pneumonitis for individual patient treatment.
Journal ArticleDOI
Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients
S.L.S. Kwa,Joos V. Lebesque,Jacqueline C.M. Theuws,Lawrence B. Marks,Mike T. Munley,Gunilla C. Bentel,Dieter Oetzel,Uwe Spahn,Mary V. Graham,Robert E. Drzymala,James A. Purdy,Allen S. Lichter,Mary K. Martel,Randall K. Ten Haken +13 more
TL;DR: The mean lung dose, NTDmean, is relatively easy to calculate, and is a useful predictor of the risk of radiation pneumonitis, based on a large clinical data set, and might be of value in dose-escalating studies for lung cancer.
Journal ArticleDOI
Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma
Jeffrey E. Bradley,Mary V. Graham,Kathryn Winter,James A. Purdy,Ritsuko Komaki,Wilson Roa,Janice K. Ryu,Walter Bosch,Bahman Emami +8 more
TL;DR: The radiation dose was safely escalated using three-dimensional conformal techniques to 83.8 Gy for patients with V(20) values of <25% (Group 1) and to 77.4 Gy for groups 1 and 2, and locoregional control was achieved in 50-78% of patients.
Journal ArticleDOI
Radiation therapy alone for stage I non-small cell lung cancer
TL;DR: Results of definitive radiation therapy for inoperable Stage I non-small cell lung remain inferior to surgical therapy, and potential methods to improve local control with radiotherapy are discussed.